We also simultaneously investigated the status of three other well-recognized PCa CSC surface biomarkers, CD44, EpCAM and CD133 on v6A3 cells, considering the molecular heterogeneity within aggressive PCa populations [51]. This evidence concerns the gene PROM1 and posterior cortical atrophy.